Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LaFleur Advancing Restart of Beacon Gold Mill and Bulk Sample for Swanson Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cipher Pharmaceuticals Inc
T.CPH
Alternate Symbol(s):
CPHRF
Healthcare
Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology...
products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 08, 2024 5:30pm
New Press Release - Cipher Pharmaceuticals Reports Second Quarter 2024 Results
(All figures are presented in U.S. Dollars)Adjusted EBITDA was $3.1 million in Q2 2024, consistent with Q2 2023Epuris sales volumes grew 13% compared to Q2 2023, continuing its growth trajectory for the fourth consecutive quarterStrong operating cash flows of $6.2 million in Q2 2024Management...
read article.
(194)
•••
Daudau11
X
Post by
Daudau11
on Aug 07, 2024 7:02pm
Keystone Financial discusses CPH
https://youtu.be/j0T7X-OXLWI?si=FBkJ_JMlyDoHtm1c Timestamp: 33:40
(6293)
•••
retiredcf
X
Post by
retiredcf
on Aug 05, 2024 12:14pm
Acquisition Reaction
Cipher Pharma made a major acquisition that they say will double their sales and profits. The new products acquired are also superior to the existing treatment, which has 71% of the USA market, so
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 01, 2024 4:00pm
New Press Release - Cipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference Call
MISSISSAUGA, ON, Aug. 1, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the second quarter of 2024 after the market close on Thursday, August 8, 2024. The Company will also hold a...
read article.
(6293)
•••
retiredcf
X
Post by
retiredcf
on Aug 01, 2024 11:47am
Someone Wants In
A bit of profit taking this morning is perfectly understandable but the bid sitiing at $12.00 would easily punch out 10 levels of Asks up to $12.70 so someone clearly wants in. GLTA
(42)
•••
Teccing
X
Comment by
Teccing
on Jul 31, 2024 12:32pm
RE:Acquires Profitable Growth Dermatology Products
Nice run the last couple days.
(2269)
•••
Betteryear2
X
Post by
Betteryear2
on Jul 29, 2024 2:24pm
Acquires Profitable Growth Dermatology Products
Craig Mull, Interim CEO commented: "Our acquisition of the Natroba™ products and the ParaPro commercial infrastructure is a pivotal step in our strategy to establish a leading dermatology
...more
(25)
•••
blueblack
X
Post by
blueblack
on Jul 29, 2024 10:53am
retirecdf look at your inbox
look at your inbox
(6293)
•••
retiredcf
X
Post by
retiredcf
on Jul 29, 2024 9:49am
Latest NR
No question that the market is extremely pleased with the just announced acquistion. Not only are we up nearly 20%, but after only 15 min, we already have one of the top 5 highest trading
...more
(6293)
•••
retiredcf
X
Post by
retiredcf
on May 25, 2024 10:56am
Ink Research
Morning Report: What is next for the freshly squeezed pharma shorts? May24, 2024 We expect regulators to publish Canadian short position data as of May 15th on Friday. If so
...more
(6293)
•••
retiredcf
X
Post by
retiredcf
on May 25, 2024 7:35am
Keystone Financial
Pretty sure this is CPH. GLTA As you review your portfolio in 2024, we encourage you to ask yourself if it included the Best Performing Stock on the entire TSX over the past year? If
...more
(6293)
•••
retiredcf
X
Post by
retiredcf
on May 20, 2024 2:15pm
Earnings Assessment
What's not to like. GLTA EPS of 20c beat estimates of 10c; revenue of $5.86M beat estimates of $5.04M. EBITDA of $3.57M beat estimates of $3.23M. Licencing revenue rose 55%. EBITDA rose 12.5
...more
(6293)
•••
retiredcf
X
Post by
retiredcf
on May 13, 2024 8:43am
Stifel
Clearly not a fan and was pretty much compelled to raise his target price. GLTA Citing valuation concerns with its shares up 85 per cent year-to-date (versus a 7-per-cent gain for the S&P/TSX
...more
(6293)
•••
retiredcf
X
Comment by
retiredcf
on May 10, 2024 10:53am
RE:RE:RE:RE:RE:RE:Cipher Pharmaceuticals Reports Fourth Quarter
Smart move! GLTA
(42)
•••
Teccing
X
Comment by
Teccing
on May 09, 2024 9:18am
RE:RE:RE:RE:RE:Cipher Pharmaceuticals Reports Fourth Quarter
Dipping my toe early
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Have you held units of a TD mutual fund through a discount broker? Learn more.
ReGen III: Pioneering a Cleaner Lubricants Future with Patented Re-Refining